Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI ® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma
RARITAN, New Jersey, January 27, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Phase 3 CARTITUDE-4 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) versus pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd) for the treatment of patients with relapsed and lenalidomide-refractory multiple myeloma met its primary endpoint of significant improvement in progression-free survival (PFS) at the first pre-specified interim analysis. As a result of meeting the primary endpoint, the Independent Data Monitoring Commi...
Source: Johnson and Johnson - January 27, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Analyzing Disparities in the Treatment of Mantle Cell Lymphoma Analyzing Disparities in the Treatment of Mantle Cell Lymphoma
Yazeed Sawalha, MD, discusses a study that analyzed how health disparities affect the likelihood of undergoing consolidated autologous stem cell transplant for mantle cell lymphoma.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 26, 2023 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news

Spermatogonial Stem Cells and Their Niche in Male (in)fertility Spermatogonial Stem Cells and Their Niche in Male (in)fertility
This review explores how single-cell RNA-sequencing of human testicular tissues has expanded our knowledge regarding testicular somatic cells and their relation to infertility.Human Reproduction (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 26, 2023 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health Journal Article Source Type: news

J. Richard Steadman, orthopedic guru for elite athletes, dies at 85
Dr. Steadman introduced surgical innovations including harnessing the body's stem cells to stimulate growth of new cartilage in injured knees. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - January 24, 2023 Category: Consumer Health News Authors: Brian Murphy Source Type: news

Lab-grown eye cells form new neural connections
Eye cells that were grown from skin-derived stem cells could be collected from 3D cultures and coaxed to form new neural connections. (Source: NIH Research Matters)
Source: NIH Research Matters - January 24, 2023 Category: Research Source Type: news

Reprogramming Astrocytes: Unlocking DLX2’s Potential to Mend the Brain
Scientists discover how to convert the brain’s glial cells into multipotent neural stem cells. (Source: The Scientist)
Source: The Scientist - January 23, 2023 Category: Science Tags: Sponsored Article Source Type: news

Post-Transplant Triplet Bests Lenalidomide Maintenance Alone in Myeloma
(MedPage Today) -- Use of a triple-drug maintenance combination appeared to improve progression-free survival (PFS) in patients with newly diagnosed multiple myeloma following induction therapy and autologous stem-cell transplantation, an interim... (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - January 17, 2023 Category: Surgery Source Type: news

Posoleucel Efficacious for Stem Cell Transplant Recipients
TUESDAY, Jan. 17, 2023 -- For recipients of allogeneic hematopoietic cell transplantation (allo-HCT) with refractory viral infections/disease, the T-cell therapy posoleucel is well tolerated and effective, according to a study published online Jan.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 17, 2023 Category: Pharmaceuticals Source Type: news

Dementia treatment could be on the way as scientists find way to replace brain cells
Scientists have proven it is possible to turn stem cells into mature neurons, paving the way for dementia treatment. (Source: Daily Express - Health)
Source: Daily Express - Health - January 13, 2023 Category: Consumer Health News Source Type: news

Autologous HSCT Improves Long-Term Survival Autologous HSCT Improves Long-Term Survival
Patients with rapidly progressive systemic sclerosis could find long-term mortality benefits from autologous hematopoietic stem cell transplantation.Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 13, 2023 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Scientists Have Reached a Key Milestone in Learning How to Reverse Aging
This study is just the first step in redefining what it means to age, and Sinclair is the first to acknowledge that it raises more questions than answers. “We don’t understand how rejuvenation really works, but we know it works,” he says. “We can use it to rejuvenate parts of the body and hopefully make medicines that will be revolutionary. Now, when I see an older person, I don’t look at them as old, I just look at them as someone whose system needs to be rebooted. It’s no longer a question of if rejuvenation is possible, but a question of when.” (Source: TIME: Health)
Source: TIME: Health - January 12, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthscienceclimate Longevity Source Type: news

Athersys shares rise as company managers meet with investors
For most of the last year, clinical-stage Athersys has been cutting costs to preserve its capital while looking for new partners to help launch its adult stem cell therapy. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 10, 2023 Category: Pharmaceuticals Authors: Mary Vanac Source Type: news

Post-HSCT Brentuximab Vedotin Plus Nivolumab Highly Effective in Hodgkin Lymphoma
(MedPage Today) -- Brentuximab vedotin (Adcetris) in combination with nivolumab (Opdivo) after autologous hematopoietic stem-cell transplantation (HSCT) resulted in improved outcomes in patients with high-risk relapsed or refractory classic Hodgkin... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 10, 2023 Category: Hematology Source Type: news

FDA grants priority review to Roche ’s bispecific antibody glofitamab for people with relapsed or refractory large B-cell lymphoma
If approved,glofitamab would be the first fixed-duration CD20xCD3 T-cell engaging bispecific antibody approved to treat the most aggressive type of non-Hodgkin lymphomaResults from the pivotal phase I/II NP30179 study showedglofitamab induced durable response rates in people with heavily pre-treated large B-cell lymphoma, with 40% achieving a complete responseGlofitamab is part of Roche ’s industry-leading portfolio of T-cell engaging bispecific antibodies, which also includes the newly FDA-approved first-in-classLunsumio to treat follicular lymphomaBasel, 6 January 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announc...
Source: Roche Investor Update - January 6, 2023 Category: Pharmaceuticals Source Type: news

FDA grants priority review to Roche ’s bispecific antibody glofitamab for people with relapsed or refractory large B-cell lymphoma
If approved,glofitamab would be the first fixed-duration CD20xCD3 T-cell engaging bispecific antibody approved to treat the most aggressive type of non-Hodgkin lymphomaResults from the pivotal phase I/II NP30179 study showedglofitamab induced durable response rates in people with heavily pre-treated large B-cell lymphoma, with 40% achieving a complete responseGlofitamab is part of Roche ’s industry-leading portfolio of T-cell engaging bispecific antibodies, which also includes the newly FDA-approved first-in-classLunsumio to treat follicular lymphomaBasel, 6 January 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announc...
Source: Roche Media News - January 6, 2023 Category: Pharmaceuticals Source Type: news